Remdesivir, approved for the treatment of COVID-19 in 2020, showed R values higher than 0.1 for OATP1B1 and OATP1B3 inhibition, whereas it was not labeled for OATP inhibition, considering its short treatment duration (up to 10 days) and short predicted effect on substrate drugs (up to 4 h only on day one). The gene discussed is SLCO1B1; the disease is COVID-19.